

Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L12 and ("factor IX" or "F.IX." or FIX)

Display: 20 **Documents in Display Format:** - **Starting with Number** 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search
Clear
Interrupt

Search History

DATE: Wednesday, April 04, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

L13	L12 and ("factor IX" or "F.IX." or FIX)	82	L13
L12	L11 and @pd<20030409	810	L12
L11	L10 and @ad<20030409	1182	L11
L10	diafilt\$7 with (protein or \$5peptide or "factor IX" or "F.IX.")	1725	L10
L9	diafilt\$7 same (protein or \$5peptide or "factor IX" or "F.IX.")	3261	L9

DB=PGPB,USPT; PLUR=YES; OP=OR

L8	L7 and ("Factor IX" or hemophilia or hemophaelia)	1	L8
L7	James near Keith	291	L7
L6	(Chandra near Webb) AND @pd>20060716	0	L6
L5	(Andrew near Dorner) AND @pd>20060716	2	L5
L4	(Nicholas near Warne) AND @pd>20060716	3	L4
L3	((Robert near Schaub) and (factor near IX)) AND @pd>20060716	0	L3
L2	((Jayne adj E) near Hastedt) AND @pd>20061026	0	L2
L1	(David near Gong) AND @pd>20061026	1	L1

END OF SEARCH HISTORY



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Wednesday

Date: 4/4/2007

Time: 20:41:32

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

 **PALM INTRANET**

Day : Wednesday

Date: 4/4/2007

Time: 20:41:32

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 22:43:15 ON 04 APR 2007)

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 22:43:36 ON 04 APR 2007

L1 200633 S ((FACTOR(3A)IX) OR (F(2A)IX) OR FIX)
L2 38 S L1 (S) (DIAFILT? OR DIAFILTRATION OR DIAFILTER?)
L3 3 S L2 (S) (POWDER OR (SPRAY(W)DRY?))
L4 3 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)
L5 298 S L1 (S) (INHAL? OR RESPIRATION OR DPI OR (DRY(W) POWDER(W) INHAL
L6 4 S L5 (S) ((DRY(W) POWDER))
L7 4 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)

=> d que 15

L1 200633 SEA ((FACTOR(3A) IX) OR (F(2A) IX) OR FIX)
L5 298 SEA L1 (S) (INHAL? OR RESPIRATION OR DPI OR (DRY(W) POWDER(W)
INHALER))

L4 ANSWER 1 OF 3 USPATFULL on STN

TI Twin-chamber syringe filled with a charge of activity-sensitive human protein

AB A twin-chamber syringe has a pyrogen-free sterile solvent in the chamber averted from the needle, and in the second chamber facing the needle a charge of activity-sensitive human protein, introduced and lyophilized in a single operation in the syringe, where it is stored, in a quantity necessary for therapeutically effective administration. The invention also relates to the filling of the syringe and the potential it offers for immediate use of activity-sensitive human proteins and for self-administration at home.

ACCESSION NUMBER: 94:99408 USPATFULL

TITLE: Twin-chamber syringe filled with a charge of activity-sensitive human protein

INVENTOR(S): Dittmann, Otto, Brensbach-Wallbach, Germany, Federal Republic of

PATENT ASSIGNEE(S): Alpha-Therapeutic GmbH, Langen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5364350		19941115
APPLICATION INFO.:	US 1992-931380		19920818 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-455344, filed on 6 Dec 1989, now patented, Pat. No. US 5176635		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1988-3806562	19880301
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rimell, Sam	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier, & Neustadt	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	316	

L4 ANSWER 2 OF 3 USPATFULL on STN

TI Twin-chamber syringe filled with a charge of activity-sensitive human protein as active substance

AB A twin-chamber syringe has a pyrogen-free sterile solvent in the chamber averted from the needle, and in the second chamber facing the needle a charge of activity-sensitive human protein, introduced and lyophilized in a single operation in the syringe, where it is stored, in a quantity necessary for therapeutically effective administration. The invention also relates to the filling of the syringe and the potential it offers for immediate use of activity-sensitive human proteins and for self-administration at home.

ACCESSION NUMBER: 93:939 USPATFULL

TITLE: Twin-chamber syringe filled with a charge of activity-sensitive human protein as active substance

INVENTOR(S): Dittmann, Otto, Brensbach-Wallbach, Germany, Federal Republic of

PATENT ASSIGNEE(S): Alpha-Therapeutic GmbH, Langen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5176635		19930105
	WO 8907934		19890908
APPLICATION INFO.:	US 1989-455344		19891206 (7)
	WO 1989-EP202		19890301

19891206 PCT 371 date
19891206 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1988-3806562	19880301
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hafer, Robert A.	
ASSISTANT EXAMINER:	Owens, Kerry	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	304	

L4 ANSWER 3 OF 3 USPATFULL on STN

TI Plasma fraction purification using silica resin bound to a ligand
AB There is provided, in accordance with practice of this invention, a process for separating Factor IX and/or Factor X from an impure protein fraction containing protein in addition to Factors IX and X. A silica resin coupled with a ligand capable of binding Factor IX and/or Factor X is provided. An aqueous solution of the impure protein fraction is applied to the ligand-coupled silica resin to thereby bind the Factor IX and/or Factor X to the resin. The Factor IX and/or Factor X is then recovered from the resin by elution.

ACCESSION NUMBER: 88:9987 USPATFULL
TITLE: Plasma fraction purification using silica resin bound to a ligand
INVENTOR(S): Herring, Steven W., San Dimas, CA, United States
PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4725673		19880216
APPLICATION INFO.:	US 1986-902155		19860829 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schain, Howard E.		
LEGAL REPRESENTATIVE:	Christie, Parker & Hale		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	619		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 1 OF 4 USPATFULL on STN

TI Hemophilia treatment by inhalation of coagulation factors

AB Hemophilia treatment by the inhalation of coagulation factors.

Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μ m or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.

ACCESSION NUMBER: 2005:10448 USPATFULL

TITLE: Hemophilia treatment by inhalation of coagulation factors

INVENTOR(S): Gong, David K., Cupertino, CA, UNITED STATES
Hastedt, Jayne E., San Carlos, CA, UNITED STATES
Schaub, Robert G., Pelham, NH, UNITED STATES
Warne, Nicholas W., Andover, MA, UNITED STATES
Dorner, Andrew J., Cambridge, MA, UNITED STATES
Webb, Chandra A., Pelham, NH, UNITED STATES
Keith, James C., Andover, MA, UNITED STATES

PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)
Nektar Therapeutics, San Carlos, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005008580	A1	20050113
APPLICATION INFO.:	US 2004-820656	A1	20040408 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461460P	20030409 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKENS & GILCHRIST, 1401 MCKINNEY, SUITE 2600, HOUSTON, TX, 77010	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	1172	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 4 USPATFULL on STN

TI Compounds to treat alzheimer's disease

AB The present invention is directed toward substituted hydroxyethylene compounds of formula (XII) ##STR1##

useful in treating Alzheimer's disease and other similar diseases.

ACCESSION NUMBER: 2002:37903 USPATFULL

TITLE: Compounds to treat alzheimer's disease

INVENTOR(S): Hom, Roy, San Francisco, CA, UNITED STATES
Mamo, Shumeye, Oakland, CA, UNITED STATES
Tung, Jay, Belmont, CA, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002022623	A1	20020221
	US 6737420	B2	20040518
APPLICATION INFO.:	US 2001-815960	A1	20010323 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191528P	20000323 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCHANT & GOULD P.C., P.O. Box 2903, Minneapolis, MN,
55402-0903
NUMBER OF CLAIMS: 141
EXEMPLARY CLAIM: 1
LINE COUNT: 7182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN
TI Methods to treat alzheimer's disease
AB The present invention is directed toward substituted hydroxyethylene
compounds of formula (XII) ##STR1##

useful in treating Alzheimer's disease and other similar diseases.

ACCESSION NUMBER: 2002:32581 USPATFULL
TITLE: Methods to treat alzheimer's disease
INVENTOR(S): Hom, Roy, San Francisco, CA, UNITED STATES
Mamo, Shumeye S., Oakland, CA, UNITED STATES
Tung, Jay, Belmont, CA, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019403	A1	20020214
	US 7119085	B2	20061010
APPLICATION INFO.:	US 2001-816876	A1	20010323 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191528P	20000323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8655	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Dry powder compositions having improved dispersivity
AB The present invention provides a highly dispersible formulation comprising
an active agent and a dipeptide or tripeptide comprising at least two
leucyl residues. The composition of the invention possesses superior aerosol
properties and is thus preferred for aerosolized administration to the
lung. Also provided are a method for (i) increasing the dispersibility of
an active-agent containing formulation for administration to the lung, and
(ii) delivery of the composition to the lungs of a subject. The surface
tension of several representative di- and tripeptides and proteins was
determined and highly surface active peptides include dileucine and trileucine.

ACCESSION NUMBER: 2001:338322 CAPLUS
DOCUMENT NUMBER: 134:357557
TITLE: Dry powder compositions having improved dispersivity
INVENTOR(S): Lechuga-Ballesteros, David; Kuo, Mei-Chang
PATENT ASSIGNEE(S): Inhale Therapeutic Systems, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032144	A1	20010510	WO 2000-US9785	20000412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389219	A1	20010510	CA 2000-2389219	20000412
EP 1223915	A1	20020724	EP 2000-922117	20000412
EP 1223915	B1	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003513031	T	20030408	JP 2001-534349	20000412
HU 200301851	A2	20030929	HU 2003-1851	20000412
HU 200301851	A3	20060728		
NZ 518401	A	20040130	NZ 2000-518401	20000412
AU 775565	B2	20040805	AU 2000-42353	20000412
AT 313318	T	20060115	AT 2000-922117	20000412
EP 1666028	A1	20060607	EP 2005-27610	20000412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
ES 2254164	T3	20060616	ES 2000-922117	20000412
US 6518239	B1	20030211	US 2000-548759	20000413
ZA 2002002855	A	20030821	ZA 2002-2855	20020411
NO 2002001800	A	20020624	NO 2002-1800	20020417
US 2003186894	A1	20031002	US 2002-313343	20021206
US 6835372	B2	20041228		
US 2005147567	A1	20050707	US 2004-985509	20041110
PRIORITY APPLN. INFO.:				
			US 1999-162451P	P 19991029
			US 1999-164236P	P 19991108
			US 1999-172769P	P 19991220
			US 2000-178383P	P 20000127
			US 2000-178415P	P 20000127
			EP 2000-922117	A3 20000412
			WO 2000-US9785	W 20000412
			US 2000-548759	A1 20000413
			US 2002-313343	A1 20021206
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

A service of the National Library of Medicine
and the National Institutes of HealthMy NCBI
[Sign In] [Reg]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Bi

Search PubMed for diafiltration protein Go Clear Save S

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

About Entrez

Text Version

All: 130 Review: 3

Items 1 - 20 of 130

Page 1 of 7 Next

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Rombaut R, Dejonckheere V, Dewettinck K. Related Articles, Links

Filtration of milk fat globule membrane fragments from acid buttermilk cheese whey.

J Dairy Sci. 2007 Apr;90(4):1662-73.

PMID: 17369206 [PubMed - in process]

2: Huang KX, Badger M, Haney K, Evans SL. Related Articles, Links

Large scale production of Bacillus thuringiensis PS149B1 insecticidal proteins Cry34Ab1 and Cry35Ab1 from Pseudomonas fluorescens.

Protein Expr Purif. 2007 Jun;53(2):325-30. Epub 2007 Jan 23.

PMID: 17337206 [PubMed - in process]

3: Bekedam EK, De Laat MP, Schols HA, Van Boekel MA, Smit G. Related Articles, Links

Arabinogalactan proteins are incorporated in negatively charged coffee brew melanoidins.

J Agric Food Chem. 2007 Feb 7;55(3):761-8.

PMID: 17263472 [PubMed - in process]

4: Kischnick S, Weber B, Verdino P, Keller W, Sanders EA, Anspach FB, Fiebig H, Cromwell O, Suck R. Related Articles, Links

Bacterial fermentation of recombinant major wasp allergen Antigen 5 using oxygen limiting growth conditions improves yield and quality of inclusion bodies.

Protein Expr Purif. 2006 Jun;47(2):621-8. Epub 2006 Feb 8.

PMID: 16495080 [PubMed - indexed for MEDLINE]

5: Wang A, Lewus R, Rathore AS. Related Articles, Links

Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth.

Biotechnol Bioeng. 2006 May 5;94(1):91-104.

PMID: 16440354 [PubMed - indexed for MEDLINE]

6: Li Z, Youravong W, H-Kittikun A. Related Articles, Links


Separation of proteases from yellowfin tuna spleen by ultrafiltration.

Bioresour Technol. 2006 Dec;97(18):2364-70. Epub 2005 Nov 28.


PMID: 16314093 [PubMed - indexed for MEDLINE]

7: Baruah GL, Nayak A, Winkelman E, Belfort G. Related Articles, Links


Purification of monoclonal antibodies derived from transgenic goat milk

 by ultrafiltration.
Biotechnol Bioeng. 2006 Mar 5;93(4):747-54.
PMID: 16255037 [PubMed - indexed for MEDLINE]


▢ 8: [Honda J](#), [Andou H](#), [Mannen T](#), [Sugimoto S](#). Related Articles, Links

 Direct refolding of recombinant human growth differentiation factor 5 for large-scale production process.
J Biosci Bioeng. 2000;89(6):582-9.
PMID: 16232802 [PubMed]


▢ 9: [Pacheco MT](#), [Sgarbieri VC](#). Related Articles, Links

 Effect of different hydrolysates of whey protein on hepatic glutathione content in mice.
J Med Food. 2005 Fall;8(3):337-42.
PMID: 16176144 [PubMed - indexed for MEDLINE]


▢ 10: [Wei JS](#), [Tao R](#), [Sun WW](#), [Jia Q](#), [Li C](#), [Liang MF](#). Related Articles

 Purification and characterization of recombinant human anti-HAV monoclonal antibody.
Sheng Wu Gong Cheng Xue Bao. 2004 Mar;20(2):257-61.
PMID: 15969118 [PubMed - in process]


▢ 11: [Bataki EL](#), [Evans GS](#), [Everard ML](#). Related Articles, Links

 Respiratory syncytial virus and neutrophil activation.
Clin Exp Immunol. 2005 Jun;140(3):470-7.
PMID: 15932508 [PubMed - indexed for MEDLINE]


▢ 12: [Leonard EF](#), [Cortell S](#), [Vitale NG](#). Related Articles, Links

 Membraneless dialysis--is it possible?
Contrib Nephrol. 2005;149:343-53. Review.
PMID: 15876858 [PubMed - indexed for MEDLINE]


▢ 13: [Nelson BK](#), [Barbano DM](#). Related Articles, Links

 A microfiltration process to maximize removal of serum proteins from skim milk before cheese making.
J Dairy Sci. 2005 May;88(5):1891-900.
PMID: 15829684 [PubMed - indexed for MEDLINE]


▢ 14: [Wan Y](#), [Vasan S](#), [Ghosh R](#), [Hale G](#), [Cui Z](#). Related Articles, Links

 Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration.
Biotechnol Bioeng. 2005 May 20;90(4):422-32.
PMID: 15812802 [PubMed - indexed for MEDLINE]


▢ 15: [George LW](#), [Borrowman AJ](#), [Angelos JA](#). Related Articles, Links

 Effectiveness of a cytolysin-enriched vaccine for protection of cattle against infectious bovine keratoconjunctivitis.
Am J Vet Res. 2005 Jan;66(1):136-42.
PMID: 15691049 [PubMed - indexed for MEDLINE]

▢ 16: [Stevens PJ](#), [Sekido M](#), [Lee RJ](#). Related Articles, Links


 A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.
Pharm Res. 2004 Dec;21(12):2153-7.

PMID: 15648245 [PubMed - indexed for MEDLINE]

 **17:** [Vallejo LF](#), [Rinas U](#).[Related Articles](#), [Links](#)**Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins.**


Microb Cell Fact. 2004 Sep 2;3(1):11.

PMID: 15345063 [PubMed - as supplied by publisher]

 **18:** [Stoner MR](#), [Fischer N](#), [Nixon L](#), [Buckel S](#), [Benke M](#), [Austin F](#), [Randolph TW](#), [Kendrick BS](#).[Related Articles](#), [Links](#)**Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations.**


J Pharm Sci. 2004 Sep;93(9):2332-42.

PMID: 15295793 [PubMed - indexed for MEDLINE]

 **19:** [George LW](#), [Angelos JA](#), [Ruehl WW](#).[Related Articles](#), [Links](#)**Stability, antigenicity, and aggregation of Moraxella bovis cytolysin after purification and storage.**

Am J Vet Res. 2004 Jul;65(7):977-83.

PMID: 15281658 [PubMed - indexed for MEDLINE]

 **20:** [Tessier PM](#), [Verruto VJ](#), [Sandler SI](#), [Lenhoff AM](#).[Related Articles](#), [Links](#)**Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross-coefficients.**

Biotechnol Bioeng. 2004 Aug 5;87(3):303-10.

PMID: 15281105 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 130

Page of 7 [Next](#)Display Show Sort by Send to [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 30 2007 06:45:50